The study included patients with a history of myocardial infarction and a high-sensitivity C-reactive protein (hs-CRP) level of ≥2 mg/L, focusing on a population with elevated inflammatory markers.4,8,19 According to the CANTOS study results, patients treated with canakinumab experienced a 15% reduction in cardiovascular events compared to the placebo group.8 Additionally, a significant decrease in hs-CRP levels was observed, with a strong correlation between reduced hs-CRP levels and decreased cardiovascular events. Here, CRP is linked to myocardial infarction.